Karyopharm Therapeutics
KPTI
60 hedge funds and large institutions have $311M invested in Karyopharm Therapeutics in 2014 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 9 closing their positions.
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
53% more capital invested
Capital invested by funds: $204M → $311M (+$107M)
11% more funds holding
Funds holding: 54 → 60 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$41.3M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$10.5M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.08M |
| 4 |
BlackRock
New York
|
+$2.59M |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$2.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$19.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.14M |
| 3 |
TG
TCW Group
Los Angeles,
California
|
-$3.91M |
| 4 |
Morgan Stanley
New York
|
-$3.52M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.72M |
KPTI Hedge Fund Activity: Q1 2014 in Review
60 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2014, worth a combined $311M — up 53% from $204M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new KPTI positions and 9 closed out — a net gain of 6 holders — while 18 added to existing stakes and 24 trimmed.
The largest buyer was Franklin Resources, adding an estimated $41.3M. The largest seller was PFM Health Sciences, cutting an estimated $19.6M.
- 60 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2014, up from 54 in Q4 2013.
- Funds reported $311M of Karyopharm Therapeutics stock for Q1 2014, up 53% quarter-over-quarter.
- 15 funds opened new Karyopharm Therapeutics positions in Q1 2014 and 9 closed out, a net change of +6 holders.
- The largest Karyopharm Therapeutics buyer in Q1 2014 was Franklin Resources, an estimated $41.3M added.
- The largest Karyopharm Therapeutics seller in Q1 2014 was PFM Health Sciences, an estimated $19.6M sold.
Based on aggregated 13F filings for Q1 2014.